StockNow
CalendarLog in
U.S. Markets

Teva (TEVA) announces positive topline results from Phase 2a study in celiac disease for its Anti-Il-15; study met primary endpoint

StockNow breaking-news AI analysis

Teva announced that its Phase 2a clinical study evaluating Anti-IL-15 for celiac disease achieved positive topline results and successfully met its primary endpoint.

1 stocks
TEVATeva Pharmaceutical Industries Limited American Depositary Shares$36.92Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

US Treasury Secretary Bessent says his advice regarding Iran and Russia is to “stay away from them,” adding that no one should support the regimes, according to a Fox News Interview

Fed

Fed's Williams (Voter, Neutral) says bond market driven by strong US economy and big investments in AI

Geopolitics

Iranian Parliament Speaker Ghalibaf says Iran does not reject negotiations but views them as a tool in its broader confrontation with the US and Israel, Tasnim reports; reiterates US must fulfill its commitments before Iran "takes steps" to reopen Hormuz